BeiGene haematology chief medical officer Mehrdad Mobasher noted that Brukinsa is the first Bruton’s tyrosine kinase inhibitor to demonstrate efficacy in follicular lymphoma. Credit: BeiGene / Business Wire.

The US Food and Drug Administration (FDA) has accepted for review BeiGene’s supplemental new drug application (sNDA) for Brukinsa (zanubrutinib) plus obinutuzumab to treat relapsed or refractory (R/R) follicular lymphoma (FL).

The treatment is indicated for use in adult R/R FL patients, following a minimum of two previous lines of therapy. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A decision on the approval for the treatment is expected in the first quarter of 2024.

Brukinsa is a small molecule Bruton’s tyrosine kinase (BTK) inhibitor that received fast track and orphan drug designation for R/R FL treatment. 

The filing is based on findings from the Phase II ROSEWOOD clinical trial in 217 R/R non-Hodgkin FL patients, who had previously received treatment. 

Safety data from the trial were in line with those from prior studies of both therapies. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Longer-term trial findings also showed that the efficacy benefit of Brukinsa plus obinutuzumab continued at a median follow-up of 20.2 months.

BeiGene haematology chief medical officer Mehrdad Mobasher stated: “Follicular lymphoma is the most common slow-growing non-Hodgkin lymphoma, but there are limited treatment options for patients whose condition has progressed after two lines of therapy.

“We are therefore pleased that Brukinsa is the first Bruton’s tyrosine kinase inhibitor to demonstrate efficacy in follicular lymphoma and plan to continue worldwide regulatory submissions based on the ROSEWOOD results.”

The submissions for Brukinsa in the same indication are under review in China, Canada, Switzerland, the European Union and the UK.

The latest development comes after the company entered a licence agreement for DualityBio’s antibody-drug conjugate therapy to treat certain solid tumours.